227
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen’s nomogram on a Norwegian cohort

, , , , , , & show all
Pages 8-15 | Received 26 Mar 2014, Accepted 25 Jul 2014, Published online: 20 Aug 2014

References

  • Kreftregisteret. Årsrapport 2013: Norwegian cancer registry. 2013. Available from http://www.kreftregisteret.no/Global/Publikasjoner og rapporter/%C3%85rsrapporter/aarsrapport_2013_Prostatakreftregisteret.pdf. cited 1 Feb 2014.
  • Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent – update 2013. Eur Urol 2014;65:124–37.
  • Batura D, Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother 2013;68:247–9.
  • Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem 2014;47:889–96.
  • Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659–67.
  • Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 2008;180:1303–8; discussion 8.
  • Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 2013;63:201–9.
  • Nygard Y, Haukaas SA, Waage JE, Halvorsen OJ, Gravdal K, Frugard J, et al. Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97% of significant prostate cancers. Scand J Urol 2013;47:211–16.
  • Hernes E, Kyrdalen A, Kvale R, Hem E, Klepp O, Axcrona K, et al. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU Int 2010;105:805–11; discussion 811.
  • Nygard Y, Haukaas SA, Halvorsen OJ, Gravdal K, Frugard J, Akslen LA, et al. A positive real-time elastography is an independent marker for detection of high-risk prostate cancers in the primary biopsy setting. BJU Int 2014;113:E90–7.
  • Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010;28:2493–8.
  • Ruffion A, Devonec M, Champetier D, Decaussin-Petrucci M, Rodriguez-Lafrasse C, Paparel P, et al. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci 2013;14:17767–80.
  • Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Comperat E, et al. Standardization of Gleason grading among 337 European pathologists. Histopathology 2013;62:247–56.
  • Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 2011;24:6–15.
  • Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol 2013; Epub ahead of print.
  • Nyberg M, Ulmert D, Lindgren A, Lindstrom U, Abrahamsson PA, Bjartell A. PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population. Scand J Urol Nephrol 2010;44:378–83.
  • Auprich M, Augustin H, Budaus L, Kluth L, Mannweiler S, Shariat SF, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 2012;109:1627–35.
  • Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012;62:204–9.
  • Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 2013;64:895–902.
  • Turo R, Forster JA, West RM, Prescott S, Paul AB, Cross WR. Do prostate cancer nomograms give accurate information when applied to European patients? Scand J Urol 2014;1–9; Epub ahead of print.
  • Abern MR, Freedland SJ. Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution? Eur Urol 2013;63:210–11; discussion 212–3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.